Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/pir.27-2-64 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Telemedicine in Emergency Department Triage and Patient Care: A Systematic Review.
Cureus
December 2024
College of Medicine, Jazan University, Jazan, SAU.
Overcrowding in emergency departments (EDs) is a global challenge, leading to prolonged waiting times and adverse patient outcomes. Telemedicine has emerged as a promising solution, enabling remote consultation, triage, and real-time specialist input. Despite its growing application, limited systematic research exists on its specific role in ED triage and care.
View Article and Find Full Text PDFAsian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis.
JACC Asia
December 2024
Department of Cardiology, National Heart Centre Singapore, Singapore.
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis (AS) and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exist a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomic variations, disparity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of AS in the Asia-Pacific region.
View Article and Find Full Text PDFImpact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
J Adv Pract Oncol
July 2024
New York Oncology Hematology, Albany, New York.
Introduction: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium™ (MYLUNG) clinical trial platform aims to advance the use of precision medicine in patients with non-small cell lung cancer through a series of prospective and iterative clinical trials. Timely patient accrual onto oncology clinical trials is a known practice challenge and impaired accrual rates can lead to premature trial closure or properly powered trial outcomes. The US Oncology Network recently implemented a clinical pharmacist (ClinReview) initiative to provide remote clinical services to screen patients for enrollment onto MYLUNG Protocol 2.
View Article and Find Full Text PDFSafety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
J Adv Pract Oncol
November 2024
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
View Article and Find Full Text PDFBackground In low-income countries, clinicians trained through a context-specific trauma surgery fellowship program (TFP) can help reduce injury-related mortality to levels closer to those observed in higher-resource settings. Successful implementation, however, hinges on buy-in from local clinicians. We therefore assessed clinician support for a potential TFP in Uganda, considering perceived need, curricular recommendations, barriers, and motivating factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!